Author:
Douša Michal,Doubský Jan,Gajdošová Michaela,Tkadlecová Marcela,Martinů Tomáš,Jireš Jakub
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference17 articles.
1. Ruxolitinib;Mesa;Nat. Rev. Drug. Discov.,2012
2. Practical management of patients with myelofibrosis receiving ruxolitinib;Harrison;Expert Rev. Hematol.,2013
3. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis;Mesa;IDrugs.,2010
4. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans;Shilling;Drug Metab. Dispos.,2010
5. Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study;Veeraraghavan;J. Pharm. Biomed. Anal.,2014
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献